Welcome to our dedicated page for Clene SEC filings (Ticker: CLNNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc.’s 10% owner Chidozie Ugwumba, through affiliated entity Symbiosis II, LLC, reported a series of indirect open‑market sales of Clene common stock. The LLC sold 15,284 shares at $4.32 on January 29, 5,686 shares at $4.13 on January 30, and 3,800 shares at $4.04 on February 2, 2026. Following the latest transaction, 555,559 shares of Clene common stock are reported as indirectly owned by Symbiosis II, LLC.
Clene Inc.’s 10% owner Ugwumba Chidozie reported a series of indirect share sales through Symbiosis II, LLC. On January 26, 2026, Symbiosis II, LLC sold 6,418 shares of Clene common stock at $5.02 per share. On January 27, 2026, it sold 4,139 shares at $5.08 per share. On January 28, 2026, it sold 8,717 shares at $4.91 per share. Following the latest transaction, Symbiosis II, LLC beneficially owned 580,329 Clene common shares indirectly attributed to the reporting person.
Clene Inc. 10% owner Ugwumba Chidozie reported indirect sales of Clene common stock through Symbiosis II, LLC. On January 22, 2026, Symbiosis II, LLC sold 12,665 shares of common stock at $5.32 per share, after which it held 605,159 shares beneficially. On January 23, 2026, it sold a further 5,556 shares at $5.27 per share, leaving 599,603 shares beneficially owned indirectly by the reporting person.
Clene Inc.'s Chief Financial Officer received a new stock option grant. On January 22, 2026, CFO Morgan R. Brown was granted a stock option covering 35,000 shares of Clene Inc. common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $5.42 per share and is reported as held directly. According to the disclosure, the options vest immediately upon grant, meaning they are fully exercisable from the grant date, and following this transaction the reporting person beneficially owns 35,000 derivative securities tied to common stock.
Clene Inc.'s Chief Science Officer, Mark Mortenson, received a new stock option grant. On January 22, 2026, he was awarded options to purchase 75,000 shares of Clene Inc. common stock at an exercise price of $5.42 per share under the Clene Inc. Amended 2020 Stock Plan. The filing notes that these options vest immediately upon grant, meaning they are fully exercisable right away. Following this grant, Mortenson holds 75,000 derivative securities (stock options) directly.
Clene Inc. reported an insider equity award for President and CEO Robert Dee Etherington, who is also a director. On January 22, 2026, he received a stock option for 75,000 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The footnote explains that these options vest immediately upon grant and are exercisable until January 21, 2036. Following this grant, Etherington directly holds 75,000 derivative securities in the form of these stock options.
Clene Inc. 10% owner Ugwumba Chidozie, through Symbiosis II, LLC, reported three open-market sales of Clene common stock. On January 16, 2026, Symbiosis II, LLC sold 7,923 shares at $5.13 per share. On January 20, 2026, it sold a further 12,432 shares at $4.80 per share, and on January 21, 2026, it sold 12,119 shares at $5.05 per share. After the last transaction, Symbiosis II, LLC indirectly held 617,824 shares of Clene common stock, reflecting the updated ownership position associated with the reporting person.
Clene Inc. reported an insider grant: Robert Dee Etherington, who is listed as both a director and the President & CEO, received a grant of option rights to purchase 10,000 shares of common stock on 09/18/2025 under the Clene Amended 2020 Stock Plan at an exercise price of $6.32 per share. The options vest immediately, are exercisable as granted, and expire on 09/17/2035. The filing shows direct beneficial ownership of the 10,000 underlying shares following the grant. The Form 4 was signed by a power of attorney on 09/19/2025.
Clene Inc. reported a compensation-related insider transaction: Chief Financial Officer Morgan R. Brown received a stock option for 10,000 shares of common stock with an exercise price of $6.32 per share. The option grant was dated 09/18/2025 and is exercisable through 09/17/2035. The filing states the options vest immediately upon grant, and following the grant the reporting person beneficially owns 10,000 underlying shares through the option. The grant was made under the company’s Amended 2020 Stock Plan.
Mark Mortenson, Chief Science Officer of Clene Inc. (CLNN / reported symbol CLNNW), was granted a stock option for 10,000 shares of common stock on 09/18/2025. The option has an exercise price of $6.32 per share, vests immediately upon grant, and expires on 09/17/2035. Following the grant, the filing reports beneficial ownership of 10,000 underlying shares attributable to the option. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 09/19/2025. The filing indicates it was submitted by one reporting person and lists the reporting person’s Salt Lake City address.